XCellAssay uses engineered cell lines and high-throughput microscopy to report on biological activities of a variety of endogenous and exogenous bioactive compounds present in body liquids.  Thousands of BioAssays can be conducted each day in miniaturized wells to which extremely small amounts of serum or urine are added. 

The unmet medical need for improved diagnostics is reflected in a Consensus Statement by the Endocrine Society that calls for "manufacturers to develop better and more cost effective assays" for hormones, particularly androgens (testosterone and testosterone-like hormones).  XCellAssay's flagship product is an 'AR BioAssay' that exhibits exquisite sensitivity and accuracy for measuring the levels of all androgens in the serum or urine of any individual, male or female.  Current techniques to evaluate androgenic activities in body liquids measure just a single hormone (testosterone).  When certain pathologic conditions require the measurement of multiple androgens, the tests used today are 15-fold more expensive and less comprehensive than the AR BioAssay measurement.  The effects of serum proteins that bind to androgens, and which differ with each individual, also is integrated uniquely into the AR BioAssay measurement.  This also improves the clinical relevance of XCellAssay's androgen measurements over that provided by the current measurement of chemically extracted testosterone.  Overall, the AR BioAssay provides a low cost, exquisitely accurate and convenient way to measure a pan-androgenic activity in ultra-low volumes of body liquids.

XCellAssay is expanding these innovative methods to enable integrated measurements for a variety of other hormone classes. Physicians and patients often request a complete diagnostic work-up of related hormones.  XCellAssay co-founders developed a cellular barcoding technology that allows a sample to be added to a mixture of assays, which will provide a panel of hormone measurements from a single finger-prick drop of blood to be collected conveniently by the patient at home.  The enhanced frequency and clinical relevance of hormone monitoring permitted by these innovative technologies will allow patients and physicians to better track treatment status and to more rapidly implement treatment alterations in response to changing need.